Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic-pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3- fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl) -2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inhibitor

Xenobiotica

Volumn 41, Issue 4, 2011, Pages 327-339

  Liederer, Bianca M ^a   Berezhkovskiy, Leonid M ^a   Dean, Brian J ^b   Dinkel, Vikki ^b   Peng, Jing ^a   Merchant, Mark ^a   Plise, Emile G ^a   Wong, Harvey ^a   Liu, Xingrong ^a  

^a GENENTECH INC   (United States)

^b ARRAY BIOPHARMA INC   (United States)

Author keywords

absorption; allometry; disposition; distribution; human prediction; MET; pharmacokinetic pharmacodynamic; pharmacokinetics

Indexed keywords

[N (4 (3 1 ETHYL 3 FLUOROPIPERIDIN 4 YLAMINO) 1H PYRAZOLO[3,4 B]PYRIDIN 4 YLOXY) 3 FLUOROPHENYL) 2 (4 FLUOROPHENYL) 3 OXO 2,3 DIHYDROPYRIDAZINE 4 CARBOXAMIDE]; ANTINEOPLASTIC AGENT; AR 00451896; UNCLASSIFIED DRUG;

ALLOMETRY; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; MALE; MOUSE; NEOPLASM; NONHUMAN; PLASMA CLEARANCE; PROTEIN BINDING; RAT;

ABSORPTION; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HAPLORHINI; HUMANS; MALE; MICE; MODELS, BIOLOGICAL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDAZINES; RATS; RATS, SPRAGUE-DAWLEY;

CANIS FAMILIARIS; MUS; RATTUS;

EID: 79952923524     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.542500     Document Type: Article

References (34)

1. Bang Y, Kawk EL, Shaw AT, Camidge DR, Iafrate AJ, Maki RG, Solomon BJ, Ou SI, Salgia R, Clark JW. (2010). Clinical Activity of the Oral ALK Inhibitor PF-02341066 in ALK-Positive Patients with Non- Small Cell Lung Cancer (NSCLC). 2010 ASCO Annual Meeting.
2. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. (2003). Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-925. (Pubitemid 37493640)
3. Boxenbaum H. (1982). Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201-227. (Pubitemid 12044187)
4. Cui JJ. (2007). Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications. Expert Opin Ther Pat 17:1035-1045. (Pubitemid 47610952)
5. Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
6. Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L, Nordlinger B, Bretti S, Bottardi S, Giordano S. (1995). Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1:147-154.
7. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. (2009). Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15:2207-2214.
8. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043. (Pubitemid 46799492)
9. Feng MR, Lou X, Brown RR, Hutchaleelaha A. (2000). Allometric pharmacokinetic scaling: Towards the prediction of human oral pharmacokinetics. Pharm Res 17:410-418. (Pubitemid 30395295)
10. Garcia A, Cunningham CC, Nemunaitis J, Li C, Rulewski N, Dovholuk A, Savage R, Chan T, Bukowksi R, Mekhail T. (2007). Phase 1 Study of ARQ 197, A Selective Inhibitor of the c-Met RTK in Patients with Metastatic Solid Tumors Reaches Recommended Phase 2 dose. 2007 ASCO Annual Meeting.
11. Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, Shariat SF. (2008). Predictive value of plasma hepatocyte growth factor/ scatter factor levels in patients with clinically localized prostate cancer. Clin Cancer Res 14:7385-7390.
12. Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, Paty PB, Weiser MR. (2007). Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 248:219-228. (Pubitemid 46330555)
13. Lee JH, Han SU, Cho H, Jennings B, Gerrard B, Dean M, Schmidt L, Zbar B, Vande Woude GF. (2000). A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 19:4947-4953.
14. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, Harbeck N. (2005). C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 113:678-682. (Pubitemid 40038747)
15. Lin JH, Yamazaki M. (2003). Clinical relevance of P-glycoprotein in drug therapy. Drug Metab Rev 35:417-454. (Pubitemid 38018115)
16. Liu X, Newton RC, Scherle PA. (2010). Developing c-MET pathway inhibitors for cancer therapy: Progress and challenges. Trends Mol Med 16:37-45.
17. Liu X, Yao W, Newton RC, Scherle PA. (2008). Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 17:997-1011.
18. Ma PC, Maulik G, Christensen J, Salgia R. (2003). c-Met: Structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 22:309-325. (Pubitemid 36791889)
19. Ma WW, Adjei AA. (2009). Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59:111-137.
20. Mager DE, Wyska E, Jusko WJ. (2003). Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31:510-518. (Pubitemid 36444157)
21. Mahmood I. (2005). Important Considerations for the Prediction of Clearance of Animals to Humans. Interspecies Pharmacokinetic Scaling. Rockville: Pine House Publishers, pp. 72-74.
22. Mahmood I, Balian JD. (1996). Interspecies scaling: Predicting clearance of drugs in humans. Three different approaches. Xenobiotica 26:887-895. (Pubitemid 26343083)
23. Maulik G, Kijima T, Ma PC, Ghosh SK, Lin J, Shapiro GI, Schaefer E, Tibaldi E, Johnson BE, Salgia R. (2002). Modulation of the c-Met/ hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 8:620-627. (Pubitemid 34193985)
24. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J. (2007). Identification of genotypecorrelated sensitivity to selective kinase inhibitors by using highthroughput tumor cell line profiling. Proc Natl Acad Sci USA 104:19936-19941.
25. Mekhail T, Rich T, Rosen L, Chai F, Semic-Suka Z, Savage RE, Senzer N. (2009). Final Results: A Dose Escalation Phase I Study of ARQ 197, A Selective c-Met Inhibitor, in Patients with Metastatic Solid Tumors. 2009 ASCO Annual Meeting.
26. Mineo R, Costantino A, Frasca F, Sciacca L, Russo S, Vigneri R, Belfiore A. (2004). Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: Biological effects of HGF in thyroid cancer cells depend on Met expression levels. Endocrinology 145:4355-4365. (Pubitemid 39120585)
27. Miyata Y, Sagara Y, Kanda S, Hayashi T, Kanetake H. (2009). Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: Correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Hum Pathol 40:496-504.
28. Peruzzi B, Bottaro DP. (2006). Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12:3657-3660. (Pubitemid 44000247)
29. Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, Bull SB, Chughtai N, Zuo D, Souleimanova M, Germain D, Omeroglu A, Cardiff RD, Hallett M, Park M. (2009). Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci USA 106:12903-12908.
30. Porter J. (2010). Small molecule c-Met kinase inhibitors: A review of recent patents. Expert Opin Ther Pat 20:159-177.
31. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, Yala S, Kanteti R, Cohen EE, Lingen MW, Martin L, Krishnaswamy S, Klein-Szanto A, Christensen JG, Vokes EE, Salgia R. (2009). The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 69:3021-3031.
32. Stella MC, Comoglio PM. (1999). HGF: A multifunctional growth factor controlling cell scattering. Int J Biochem Cell Biol 31:1357-1362.
33. Wakelee HA, Gettinger SN, Engelman JA, Janne PA, West HJ, Subramaniam DS, Leach JW, Wax MB, Yaron Y, Lara P Jr. (2010). A Phase Ib/II Study of XL184 (BMS 907351) with and without Erlotinib (E) in Patients (pts) with Non-Small Cell Lung Cancer (NSCLC). 2010 ASCO Annual Meeting.
34. Yu S, Li S, Yang H, Lee F, Wu JT, Qian MG. (2005). A novel liquid chromatography/tandem mass spectrometry based depletion method for measuring red blood cell partitioning of pharmaceutical compounds in drug discovery. Rapid Commun Mass Spectrom 19:250-254. (Pubitemid 40175478)